Abstract
As the European Community moves toward harmonization of drugs, the use of class labeling has become an issue. Class labeling for efficacy is always, sometimes, or never appropriate—depending on the circumstances, which are reviewed in this paper. When considering class labeling, a balance between transparency and adequate individualization of labeling must be sought.
Get full access to this article
View all access options for this article.
